Download PDFPDF
Erythropoietin treatment in patients with chronic heart failure: a meta-analysis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Risk of Bias in Meta-analysis on Erythropoietin-stimulating Agents in Heart Failure
    • Benjamin P. Geisler, MD
    • Other Contributors:
      • Rob van Dam, MSc, PhD, G. Scott Gazelle, MD, MPH, PhD, and Alexander Goehler, MD, MSc, MPH

    To the editor: We are delighted by the encouraging results reported in van der Meer et al.'s meta-analysis [1] regarding lower hospitalization rates of erythropoiesis-stimulating agents (ESAs) in heart failure (HF). However, the possibility of bias in the studies included in the meta- analysis might be greater than assessed by the authors.

    First, the methodological quality of the reviewed studies was limited accor...

    Show More
    Conflict of Interest:
    None declared.